155 related articles for article (PubMed ID: 37793861)
1. [Hematological malignancies driven by aberrant splicing].
Zang W; Saika W; Aoyama Y; Inoue D
Rinsho Ketsueki; 2023; 64(9):875-883. PubMed ID: 37793861
[TBL] [Abstract][Full Text] [Related]
2. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
3. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
Kataoka N; Matsumoto E; Masaki S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
6. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
Figg JW; Barajas JM; Obeng EA
Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
[TBL] [Abstract][Full Text] [Related]
8. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
9. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanisms of myeloid malignancies].
Matsui H
Rinsho Ketsueki; 2021; 62(8):883-891. PubMed ID: 34497227
[TBL] [Abstract][Full Text] [Related]
11. Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research.
Samy A; Ozdemir MK; Alhajj R
Sci Rep; 2023 Feb; 13(1):2704. PubMed ID: 36792691
[TBL] [Abstract][Full Text] [Related]
12. RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies.
Li Z; He Z; Wang J; Kong G
J Leukoc Biol; 2023 Feb; 113(2):149-163. PubMed ID: 36822179
[TBL] [Abstract][Full Text] [Related]
13. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
14. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
15. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
18. [Splicing factor mutations in myelodysplastic syndromes].
Shiozawa Y
Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
[TBL] [Abstract][Full Text] [Related]
19. Splicing factor gene mutations in hematologic malignancies.
Saez B; Walter MJ; Graubert TA
Blood; 2017 Mar; 129(10):1260-1269. PubMed ID: 27940478
[TBL] [Abstract][Full Text] [Related]
20. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
